GovChime

Chemistry/Immunology Reagents/Analyzer

Overview

Response deadline
11:00 AM HST
Posted
November 19, 2026
Notice type
Special Notice
Set-aside
No Set aside used
Agency
Department of WarDEFENSE HEALTH AGENCY (DHA)

Notice details

Office
DEFENSE HEALTH AGENCY HCD WEST
Last updated
Nov 19, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
HT941027N0014
Notice ID
bf19497f9cfc4dc4855e9bbc6a1848ae

Description

Notice of Intent to Sole Source
HT941027N0014

THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE PURCHASE ORDER CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES. 

The Defense Health Agency Contracting Activity (DHACA), Healthcare Contracting Division – San Diego (HCD-SD), Echo Branch intends to award a firm fixed price five (5)-Year Purchase order RFO 12.102 (b) for acquisitions valued over the SAT, only one source being available to meet the Government’s needs, to:

ORTHO CLINICAL DIAGNOSTICS SINGAPORE PTE LTD, KOREA BRANCH
366 HANGANG-DAERO
YONGSAN-GU, SEOUL, 04323 SOUTH KOREA
UEI: JNSJRDQQH2J6
CAGE: 767DF

The North American Industry Classification System (NAICS) code for this requirement is 325413 - Pharmaceutical Preparation Manufacturing; the business size standard is 1,250 (in number of employees). The Product Service Code (PSC) is 6550 – Invitro Diagnostics Substances Reagents

The objective of this sole source award is to procure Chemistry/Immunology Reagents with Analyzer for Brian D. Allgood Army Community Hospital, South Korea for the Department of Pathology.
 
The contractor-furnished chemistry and immunology analyzers shall be capable of providing complete chemistry and immunochemistry testing. The entire analyzer system shall be serviced and supplied through a single Contractor awarded the contract, including all parts, equipment, and supplies not manufactured, provided, or serviced directly by the Contractor.

The system shall provide redundancy to ensure continuous operations. Each analyzer shall have the capacity to perform both chemistry and immunology assays. The Contractor shall provide the system, training, supplies, reagents, unscheduled maintenance, and preventive maintenance. All equipment displays and supporting literature shall be in English.

The Contractor shall include delivery, installation, all calibrators and standards, reagents and reagent packs, and quality-control materials necessary to perform the specified assays. The Contractor shall also perform initial method validations in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines. The Contractor shall remove the analyzers upon contract termination.

Rationale Justifying:
Ortho Clinical Diagnostics Singapore Pte. Ltd., Korea Branch, a division of QuidelOrtho Corporation, is the sole manufacturer capable of providing clinical chemistry and integrated chemistry/immunoassay analyzers that meet the Government’s test-volume requirements without requiring a facility water supply.

The Defense Health Agency requires analyzers that use 100 percent waterless, dry-slide technology. These sites cannot receive reagent-grade water into the facility for safe, quality laboratory testing and are not approved by the state to discharge biohazardous waste into any drain. This technology is unique to QuidelOrtho’s VITROS® line of analyzers and is essential to meeting the agency’s operational and mission requirements for the following reasons:

Infrastructure Independence: VITROS dry-slide technology eliminates the need for water, plumbing, and drains. This is a critical advantage in military healthcare environments, where logistical footprints must be minimized. It ensures operational continuity and significantly reduces infrastructure dependencies.

Enhanced Quality and Reliability: The system uses disposable tips for each sample, eliminating the risk of sample-to-sample carryover and reagent-to-reagent contamination that can occur in traditional wet-chemistry systems. This supports the accuracy and reliability of test results for patient care, particularly for high-acuity, time-sensitive assays.

For example, emergency physicians rely on rapid, accurate first-run results for high-sensitivity troponin to triage potential heart attacks; procalcitonin and lactic acid to diagnose life-threatening sepsis; and potassium levels to treat sudden acute renal or metabolic failure. In these life-threatening situations, a false or contaminated initial result can delay critical medical intervention. The dry-slide technology’s elimination of sample carryover helps ensure that providers can rely on the initial result when time is of the essence.

Laboratory Productivity: Reagents are self-contained in a dry-slide format that provides calibration stability of up to six months for most assays. This extended calibration interval substantially reduces the time and labor associated with daily calibration and quality-control procedures while also reducing reagent waste.systems. This ensures the highest accuracy and reliability of test results for patient care, which is absolutely critical for high-acuity, time-sensitive assays. For example, emergency physicians rely on rapid, flawless first-time results for high sensitivity troponin to triage imminent heart attacks, procalcitonin and lactic acid to diagnose life-threatening sepsis, and potassium levels to treat sudden acute renal or metabolic failure. In these life-or-death scenarios, a false or contaminated first read delays vital medical interventions; the dry-slide technology's elimination of sample carryover ensures providers can trust the initial result when time is of the essence. Laboratory Productivity: Reagents are self-contained in a dry-slide format that provides up to a six-month calibration stability for most assays. This extended frequency drastically reduces the time and labor spent on daily calibration and quality control procedures while decreasing reagent waste.


Product List:

Chemistry/Immunology Annual Test Count                        
Test         Base Year          6-Month      Option Year I    Option Year II     Option Year III      Option Year IV 
1    ACETAMINOPHEN     1,541      1,731      1,783      1,836      1,891 
2    ALBUMIN     9,202      17,513      18,038      18,579      19,136 
3    ALANINE AMINOTRANSFERASE     9,209      17,529      18,055      18,597      19,155 
4    ALKALINE PHOSPHATASE     9,285      17,684      18,215      18,762      19,325 
5    AMYLASE     1,470      1,586      1,634      1,683      1,734 
6    ASPARTATE AMINOTRANSFERASE     9,914      18,980      19,549      20,136      20,740 
7    BILIRUBIN TOTAL     9,581      18,295      18,844      19,409      19,991 
8    BILIRUBIN DIRECT     1,343      2,088      2,151      2,216      2,283 
9    BILIRUBIN CONJUGATED     662      1,003      1,033      1,064      1,096 
10    BILIRUBIN UNCONJUGATED     662      1,003      1,033      1,064      1,096 
11    BILIRUBIN NEONATAL     85      132      136      140      144 
12    CALCIUM     9,642      18,420      18,973      19,542      20,128 
13    CARBON DIOXIDE     9,626      18,387      18,939      19,507      20,092 
14    CHLORIDE     9,771      18,686      19,247      19,824      20,419 
15    CHOLESTEROL TOTAL     4,951      8,757      9,020      9,291      9,570 
16    CK-MB     1,992      2,660      2,740      2,822      2,907 
17    C-REACTIVE PROTEIN     2,349      3,396      3,498      3,603      3,711 
18    CREATININE     10,084      19,360      19,941      20,539      21,155 
19    CREATININE, RANDOM URINE     206      396      408      420      433 
20    CREATINE KINASE     1,993      2,663      2,743      2,825      2,910 
21    ETHANOL     2,674      4,065      4,187      4,313      4,442 
22    G-GLUTAMYL TRANSFERASE     2,195      3,079      3,171      3,266      3,364 
23    GENTAMICIN PEAK     834      579      596      614      632 
24    GENTAMICIN TROUGH     222      154      159      164      169 
25    GLUCOSE     10,228      19,784      20,378      20,989      21,619 
26    GLUCOSE 1ST    46     89      92      95      98 
27    GLUCOSE 2ND    46     89      92      95      98 
28    GLUCOSE 3RD    46     89      92      95      98 
29    GLUCOSE POSTPRANDIAL    3     4      4      4      4 
30    GLUCOSE POST 50G GLUCOLA 1H    149     288      297      306      315 
31    GLUCOSE POST 75G GLUCOLA 2H    12     23      24      25      26 
32    GLUCOSE FASTING    918     1,775      1,828      1,883      1,940 
33    GLUCOSE CSF    23     44      45      46      47 
34    HDL CHOLESTEROL     4,879      8,609      8,867      9,133      9,407 
35    IRON     1,465      1,575      1,622      1,671      1,721 
36    LACTATE     1,647      1,951      2,010      2,070      2,132 
37    LACTATE DEHYDROGENASE     1,476      1,598      1,646      1,695      1,746 
38    LIPASE     2,637      3,990      4,110      4,233      4,360 
39    MAGNESIUM     2,103      2,889      2,976      3,065      3,157 
40    PHOSPHORUS     1,823      2,312      2,381      2,452      2,526 
41    POTASSIUM     10,047      19,254      19,832      20,427      21,040 
42    PROTEIN     9,075      17,253      17,771      18,304      18,853 
43    PROTEIN CSF     847      303      312      321      331 
44    PROTEIN, RANDOM URINE     1,184      996      1,026      1,057      1,089 
45    SALICYLATES     1,520      1,689      1,740      1,792      1,846 
46    SODIUM     10,568      20,327      20,937      21,565      22,212 
47    TRIGLYCERIDE     4,983      8,822      9,087      9,360      9,641 
48    UREA NITROGEN     9,808      18,761      19,324      19,904      20,501 
49    URIC ACID     1,556      1,762      1,815      1,870      1,926 
50    VANCOMYCIN PEAK     574      446      459      473      487 
51    VANCOMYCIN TROUGH     551      429      442      455      469 
52    HCG QN     2,628      3,972      4,091      4,214      4,340 
53    THYROTROPIN     5,327      9,531      9,817      10,112      10,415 
54    T4 FREE     2,318      3,332      3,432      3,535      3,641 
55    THYROXINE, TOTAL     1,950      2,575      2,652      2,732      2,814 
56    TROPONIN I CARDIAC     2,855      4,438      4,571      4,708      4,849 
57    HEPATITIS B SURFACE AG     3,435      5,633      5,802      5,976      6,155 
58    HEPATITIS B SURFACE AB     3,848      6,485      6,680      6,880      7,086 
59    HEPATITIS B CORE AB TOTAL     3,522      5,183      5,339      5,500      5,665 
60    HEPATITIS C AB     3,193      5,136      5,290      5,449      5,613 
61    HEPATITIS A IGM     2,675      4,068      4,190      4,316      4,446 
62    HEPATITIS A AB, TOTAL     2,964      4,663      4,803      4,947      5,095 
63    RUBELLA VIRUS IGG     1,724      2,108      2,171      2,236      2,303 
64    HBA1C-IFCC, NGSP     4,668      8,173      8,418      8,671      8,931 
65    PRO-BNP     2,322      3,341      3,441      3,544      3,650 
 


Agency and Requirement Description and Market Research Conducted:

DHA HCD-SD is supporting Brian D. Allgood Army Community Hospital in South Korea, with a  requirement for Chemistry/Immunology Reagents with Analyzer. Specifically, this requirement is for  tests in the product list above. 
Extensive market research through the General Services Administration (GSA), Federal Supply Schedules (FSS), or other mandatory sources. Broad database searches were conducted across FPDS-NG, GSA Advantage, GSA eLibrary, GSA Global Supply, NASA SEWP, and VA FSS using keywords such as “Chemistry”.  These searches either yielded zero results or failed to identify contractors capable of providing the exact or equal supplies required. Additionally, a review of internal contracting activity via the BPA Tracker revealed no similar contracts currently in place to leverage. Open market research, including internet searches and personal telephone contacts with potential vendors, confirmed that while "Chemistry/Immunology Reagents/Analyzers" are commercially available RFO 12.102(b) only Ortho Clinical Diagnostics Singapore PTE LTD, Korea Branch is the only vendor that can meet the agency's requirements.

Delivery location: 

BRIAN D. ALLGOOD ARMY COMMUNITY HOSPITAL 
348TH QM CO SRA BLDG 
1603 CAMP HUMPHREYS PYEONGTAEK, 17982

Estimated Delivery Schedule: 1 April 2027 to 30 September 2031 (Including a 6 month base period and four (4) 12 month option years).

Based on market research and previous acquisition history, it has been determined that Ortho Clinical Diagnostics Singapore PTE LTD, Korea Branch, is the only source that can meet the Government’s minimum requirements to provide chemistry/immunology reagents and analyzer for the Brian D. Allgood Army Community Hospital. 

This notice of intent is not a request for competitive proposals, and no solicitation document exists for this requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to provide the chemistry/immunology reagents and analyzer for the Brian D. Allgood Army Community Hospital. Capability statements shall not exceed two (2) (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source purchase order.

If a vendor challenges the basis of this requirement, please email capability statements as a Microsoft Word or Adobe PDF attachment to Contract Specialist Susan Fujita at susan.m.fujita.civ@health.mil  and Contracting Officer Cha-on P. Gordon at cha-on.p.gordon2.civ@health.mil.  The closing date for challenges is no later than 11:00 a.m. (Hawaii Time), Thursday December 3, 2026. 

NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED. 


 


 

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Documents

No documents available.

Lifecycle

  1. 1
    Version 1Special NoticeCurrent

    Chemistry/Immunology Reagents/Analyzer

    Notice bf19497f9cfc4dc4855e9bbc6a1848ae on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

HT941027N0014

Archive Date

Dec 4, 2026

Place of Performance Country

KOREA, SOUTH

Office Address

CAMP PENDLETON, CA, 92055